Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Clin Cancer Res. 2019 Apr 2;25(13):3934–3945. doi: 10.1158/1078-0432.CCR-19-0081

Figure 4: Tumor killing with combination immunotherapy is mediated by T cell activity.

Figure 4:

(a) Percent of all cells per high-powered field positive for cleaved-Caspase-3 on IHC. Unpaired student’s t-tests, **p<0.01. Representative images after treatment for 6 days in vitro (scale bars 50μm). Experiment repeated in 3 patients showing similar results. (b-d) Representative flow cytometric analysis of disaggregated tumor slices after 2 days of treatment in vitro. Immune cell percentage increased with combination immunotherapy, driven mostly by both CD4+ and CD8+ T cells. Data representative of 3 total experiments. (e-f) TCR sequencing and cytokine quantification of supernatant from slices from the same tumor treated for 2 days. (e) Each bar represents a TCR clone present across slices in different treatment groups. (f) Supernatant was tested for presence of granzyme B and IFN-γ after 2 days in culture.